Founded in 1998, as Takeda's largest business unit outside of Japan, the U.S. Business Unit continues to be a key contributor to our global growth and success. We contribute to 30 percent of the company’s global revenues.
U.S. Business Unit focuses its efforts on medicines for the central nervous system (CNS) and gastroenterology (GI), with the recent FDA approvals of Trintellix and Entyvio, respectively.